Rinvoq ER 30 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DR26F9CP4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $69,114
Award facts
- Contract value 100% obligated
- $69,114.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $69,114.00 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 30 mg tablets (30-count units) on November 20, 2025, with an ultimate completion date of November 21, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.999 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs through its extensive portfolio of brand-name and generic medications, vaccines, and specialized healthcare commodities. The company's selection for this delivery order demonstrates its capability to fulfill federal pharmaceutical requirements through the DLA's competitive procurement process. RINVOQ (upadacitinib) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the breadth of specialty pharmaceuticals supplied through AmerisourceBergen's federal contracts to support military and veteran healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F9CP4?
SPE2DR26F9CP4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26F9CP4 worth?
The government has obligated $69,114 on SPE2DR26F9CP4.
Is contract SPE2DR26F9CP4 an order under another contract?
Yes. SPE2DR26F9CP4 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9CP4 competed?
The extent of competition for SPE2DR26F9CP4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award